RMD ResMed Inc.

ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023

ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023

SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

 • Location:
 • Date: Thursday, August 3, 2023
 • Time:1:30 p.m. PDT / 4:30 p.m. EDT
 • International:London, Thursday, August 3, 2023, 9:30 p.m. BST
    Sydney, Friday, August 4, 2023, 6:30 a.m. AEST

Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from August 3, 2023, until August 17, 2023, at:

 • U.S.: +1 877.660.6853
 • International: +1 201.612.7415
 • Conference ID: 13739812

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investorsFor media
Amy WakehamJayme Rubenstein
+1 858.836.5000+1 508.769.8440

 



EN
06/07/2023

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

19h / 15m 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Receives FDA Clearance for Personalized Therapy Comfort Setting...

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Setting...

December 8, 2025 1 EN
Free Trial
RMD RESMED INC.

ResMed Inc: 1 director

A director at ResMed Inc sold/sold after exercising options 2,055 shares at 255.000USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

11/26/25 November 26, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 202...

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) to...

October 30, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 202...

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Thursday, October 30, 2025 •Time:1:30 p.m. PD...

October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch